Mesa Laboratories (NASDAQ:MLAB) was downgraded by research analysts at TheStreet from a “b-” rating to a “c” rating in a research note issued on Wednesday.
Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research report on Friday, November 10th. BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th.
Mesa Laboratories (MLAB) traded up $0.94 during trading on Wednesday, hitting $133.50. 885 shares of the stock traded hands, compared to its average volume of 18,561. The stock has a market capitalization of $504.22, a P/E ratio of -131.21 and a beta of 0.52. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.97 and a current ratio of 2.37. Mesa Laboratories has a 1-year low of $117.58 and a 1-year high of $169.80.
In other news, Director John Bradley Schmieder sold 3,000 shares of Mesa Laboratories stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the director now directly owns 77,869 shares of the company’s stock, valued at $10,299,732.63. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 15.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in MLAB. Conestoga Capital Advisors LLC grew its position in Mesa Laboratories by 13.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 423,804 shares of the medical instruments supplier’s stock valued at $52,679,000 after purchasing an additional 50,577 shares in the last quarter. Victory Capital Management Inc. grew its position in Mesa Laboratories by 17.2% during the fourth quarter. Victory Capital Management Inc. now owns 172,774 shares of the medical instruments supplier’s stock valued at $21,476,000 after purchasing an additional 25,306 shares in the last quarter. Vanguard Group Inc. grew its position in Mesa Laboratories by 10.1% during the second quarter. Vanguard Group Inc. now owns 145,161 shares of the medical instruments supplier’s stock valued at $20,804,000 after purchasing an additional 13,263 shares in the last quarter. Thomson Horstmann & Bryant Inc. grew its position in Mesa Laboratories by 14.5% during the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 88,379 shares of the medical instruments supplier’s stock valued at $10,985,000 after purchasing an additional 11,164 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Mesa Laboratories during the third quarter valued at approximately $1,470,000. 71.29% of the stock is currently owned by hedge funds and other institutional investors.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.